Tag: Drug Development

sanofi-acquires-new-alzheimers-drug-expansion-of-pipeline

Sanofi Acquires New Alzheimer’s Drug: Expansion of Pipeline

Sanofi Snags Vigil Neuroscience for Alzheimer's DrugSo, like, Sanofi, the French drug maker, just dropped $470 million to acquire Vigil Neuroscience, a small biotech company. And get this, they're adding an experimental treatment for...
summit-therapeutics-clinical-trial-update-what-you-need-to-know

Summit Therapeutics Clinical Trial Update: What You Need to Know

Adam Feuerstein, a seasoned writer and biotech columnist, dives into the world of drug development, business, Wall Street, and biotechnology. He wears many hats as a co-host of the weekly biotech podcast The Readout...
threat-to-pharmaceutical-public-private-partnerships-gileads-short-term-win

Threat to Pharmaceutical Public-Private Partnerships: Gilead’s Short-Term Win

In December 2024, a group of legal, medical, and public health experts united to file an amicus brief in support of the U.S. government in a groundbreaking patent lawsuit against Gilead Sciences Inc., a...
news-28102024-163033

David Epstein launches new cancer startup after Novartis and Seagen career

David Epstein, who previously served as the CEO of Seagen, has launched a new cancer startup called Ottimo Pharma. The company aims to develop a drug that targets two proteins, PD-1 and VEGF, in...
news-21102024-091557

Seaport Therapeutics Secures $225 Million to Advance Neuroscience Innovation in the ‘Golden Age’

Seaport Therapeutics, a new biotech startup led by the team from Karuna Therapeutics, has successfully secured an additional $225 million in funding just half a year after its last fundraising effort. The Series B...
news-20102024-090918

RSV Prophylactic Beyfortus: Potential Competitors and Market Trends

Alnylam Pharmaceuticals, led by CEO Yvonne Greenstreet, is making strides in expanding the use of its RNA-based gene-silencing heart drug, vutrisiran. The drug has shown promising results in reducing the risk of death and...
news-13082024-014827

FDA Rejects MDMA and Nasal Spray for Allergic Reactions: Pharmalittle Update

Good morning everyone, hope you had a restful weekend and are ready to tackle the new week ahead. As we sip on some refreshing blueberry cobbler, let's dive into some interesting updates. The U.S....
news-12082024-194709

Pfizer CEO’s Vision for Leading Cancer and Obesity Treatments

Albert Bourla, the CEO of Pfizer, is looking to shift the focus of the company from its successful COVID-19 vaccine and antiviral Paxlovid to new investments in drugs for cancer and obesity. While Pfizer's...
news-04082024-054201

New Title: Soft-Tissue Cancer Drug Approval and Zepbound Shortage Update: Pharmalittle News

Good morning, this is Jonathan Wosen, reporting on the latest news in the biotech and life sciences world. The FDA has recently approved a new treatment for a rare soft tissue cancer. This cutting-edge...

BREAKING NEWS

Top News